Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Journal
Hepatology international
Date Issued
2023-01-26
Author(s)
Peng, Cheng-Yuan
Chen, Chi-Yi
Lo, Ching-Chu
Tseng, Kuo-Chih
Su, Pei-Yuan
Kao, Wei-Yu
Tsai, Ming-Chang
Tung, Hung-Da
Cheng, Hao-Tsai
Lee, Fu-Jen
Huang, Chia-Sheng
Huang, Ke-Jhang
Shih, Yu-Lueng
Yang, Sheng-Shun
Wu, Jo-Hsuan
Lai, Hsueh-Chou
Chen, Po-Yueh
Hwang, Jow-Jyh
Tseng, Chi-Wei
Su, Wei-Wen
Chang, Chun-Chao
Lee, Pei-Lun
Chen, Jyh-Jou
Chang, Chi-Yang
Hsieh, Tsai-Yuan
Chang, Chung-Hsin
Huang, Yi-Jie
Abstract
Real-world data are scarce about the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivirals (DAAs). We conducted a multicenter study to assess the performance of SOF/VEL/VOX in patients who were not responsive to prior NS5A inhibitors in Taiwan.
Subjects
Direct-acting antiviral; Effectiveness; Hepatitis C virus; Pangenotypic; Resistance-associated substitution; Safety; Sofosbuvir; Sustained virologic response; Velpatasvir; Voxilaprevir
SDGs
Publisher
SPRINGER
Type
journal article